Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

The potential for hormonal prevention trials

L G Ford1, O W Brawley, J A Perlman

  • 1Detection and Community Oncology Program, National Cancer Institute, Bethesda, Maryland 20892.

Cancer
|November 1, 1994
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Five-alpha-reductase Inhibitors for prostate cancer prevention.

The Cochrane database of systematic reviews·2008
Same author

Evidence of a healthy volunteer effect in the prostate, lung, colorectal, and ovarian cancer screening trial.

American journal of epidemiology·2007
Same author

Trends in biomarker research for cancer detection.

The Lancet. Oncology·2002
Same author

Good for women, good for men, bad for people: Simpson's paradox and the importance of sex-specific analysis in observational studies.

Journal of women's health & gender-based medicine·2001
Same author

The paired availability design for historical controls.

BMC medical research methodology·2001
Same author

Relationship of demographic and clinical factors to free and total prostate-specific antigen.

Urology·2001
Same journal

Long-term outcomes of evolving treatment regimens in Ewing sarcoma survivors diagnosed 1970-1999: A report from the Childhood Cancer Survivor Study.

Cancer·2026
Same journal

Large-scale osteosarcoma sequencing reveals age-associated genomic architectures.

Cancer·2026
Same journal

EZH2 inhibitor tazemetostat voluntarily withdrawn from market.

Cancer·2026
Same journal

Nivolumab and chemotherapy combination approved for previously untreated Hodgkin lymphoma.

Cancer·2026
Same journal

Most older patients with advanced cancer prioritize QOL over extending survival: A secondary analysis of the GAP70+ trial found that among adults aged 70 and older with advanced, noncurable cancer, nearly three-quarters prioritized maintaining QOL.

Cancer·2026
Same journal

Real-world safety, prognostic, and design considerations in ketogenic diet trials for pancreatic cancer.

Cancer·2026
See all related articles

Hormonal interventions like tamoxifen for breast cancer and finasteride for prostate cancer are being studied in large trials. These studies aim to determine if these drugs can prevent cancer development and offer insights into cancer risk and prevention strategies.

Area of Science:

  • Oncology
  • Endocrinology
  • Preventive Medicine

Background:

  • Breast and prostate cancers share similar causes, risk factors, and treatments.
  • Hormonal manipulation is a key area of investigation for cancer prevention.
  • Large-scale clinical trials are crucial for evaluating preventive interventions.

Purpose of the Study:

  • To evaluate the efficacy of hormonal agents in preventing breast and prostate cancer.
  • To assess the impact of tamoxifen on breast cancer development in high-risk women.
  • To determine if finasteride reduces prostate cancer incidence in older men.

Main Methods:

  • The Breast Cancer Prevention Trial randomizes 16,000 high-risk women to tamoxifen or placebo for 5 years.
  • The Prostate Cancer Prevention Trial randomizes 18,000 men over 55 to finasteride or placebo.

Related Experiment Videos

  • Both trials involve prolonged hormonal intervention to assess cancer incidence.

    • Main Results:

    • The trials are designed to demonstrate if hormonal interventions can significantly decrease cancer risk.
    • Data from these trials will provide critical information on cancer etiology and genetics.
    • Quantification of the risks and benefits associated with specific preventive strategies will be obtained.

    Conclusions:

    • Hormonal interventions hold promise for reducing the incidence of breast and prostate cancers.
    • These large clinical trials are essential for advancing our understanding of cancer prevention.
    • Findings will inform future strategies for cancer risk assessment, screening, and personalized prevention.